Home MarketDr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd. Stock Info: As on 2018-02-23 15:56:49

Nse

905.60

-0.25(-0.03%)
Change%
52 Week Range
723.05
24.00
1,000.00
22.00
Open913.00
Day's Range724.68 - 1,087.02
Value Traded (in ₹ Cr.) 1.22

Bse

908.00

3.30(0.36%)
Change %
52 Week Range
717.65
24.00
1,002.00
22.00
Open904.20
Day's Range723.76 - 1,085.64
Value Traded (in ₹ Cr.) 0.06

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 47,848,562.00 57.42%
Mutual Funds/UTI 10,408,502.00 12.49%
FII 8,728,094.00 10.47%
Employee 0.00 0.00%
Public 4,326,140.00 5.19%
Government 0.00 0.00%
Others 9,907,909.00 11.89%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 9.95
Basic EPS (Rs.) 15.31
Cash EPS 19.08
BVPerShare Excl 57.88
Operating Revenue 92.58
PBDITPerShare 27.12
Dividend 2.45
NPPerShare 15.21
Current Ratio 4.68
Quick Ratio 4.52
PriceToBV 15.92
Earnings 0.01
PBDIT Margin 29.29
PBT Margin 25.05
NP Margin 16.42
Return On Assets 21.25
Retention Ratios 83.87
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 785.81
Total Expenses 594.05
EBITDA 224.25
PBT 191.75
PAT 125.75
Net Income 125.75
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 384.69
Total Expenses 268.78
EBITDA 99.39
PBT 132.23
PAT 92.43
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 82.68
Net worth 478.51
Investments 74.18
Total Liability 591.72
Total debt 0.00
Net block 133.88
Total Assets 591.72
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 81.26
Net worth 319.24
Investments 49.36
Total Liability 449.18
Total debt 0.00
Net block 119.97
Total Assets 449.18
Company Curr Price Prev. Close Change% W's Low/High

Apollo Hospitals Enterprise Ltd.

1231.6 1246.45 -1.19
11221250

Fortis Healthcare Ltd.

159.95 146.3 9.33
116.15159

Healthcare Global Enterprises Ltd.

302.65 303.15 -0.16
298333.5

Indraprastha Medical Corporation Ltd.

54.4 53.85 1.02
53.157.45

Kovai Medical Center and Hospital Ltd.

641.65 624.85 2.68
629.9649.9

Lotus Eye Hospital and Institute Ltd.

29.8 30.85 -3.4
29.733.45

Marico Kaya Enterprises Ltd.

1547.05 1582.55 -2.24
1535.051589
Company Curr Price Prev. Close Change% W's Low/High

ADS Diagnostic Ltd.

11.34 10.8 0
11.3411.34

Apollo Hospitals Enterprise Ltd.

1238 1244.6 -0.53
11211258.55

Birla Pacific Medspa Ltd.

0.28 0.27 0
0.270.28

CDR Health Care Ltd.

7.58 2.6 0
7.227.58

Chennai Meenakshi Multispeciality Hospital Ltd.

26.35 26.85 -1.86
26.8529

Dhanvantri Jeevan Rekha Ltd.

34.5 35.4 -2.54
32.536.4

Dolphin Medical Services Ltd.

1.25 1.31 -4.58
1.281.35
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 142.25
Cash from investing activities -148.14
Cash from financing activities 0.99
Net change in cash -4.89

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Franklin India Prima Plus 1.47%
Franklin India Smaller Companies Fund 1.83%
SBI Blue Chip Fund 0.44%
SBI Magnum Midcap Fund 1.75%
UTI Equity Fund 1.25%
SBI Magnum Global Fund 1.51%

L&T’s arm bags orders worth Rs 1,266 cr

Larsen & Toubro has said that its construction arm has won orders worth Rs 1,266 crore across various business segments. The Buildings & Factories Business bagged orders worth Rs 928 crore. The order was bagged from a reputed government client to construct 284 Residential towers of G+3 floors under the Prime Minister Awas Yojana Scheme in various locations of Krishna District of Andhra Pradesh. The Power Transmission and Distribution business & Transportation Infrastructure business bagged an order from the Mumbai Metro Rail Corporation Ltd. (MMRC) worth Rs 338 Crore. The project involves Design, Engineering, Supply, Installation, Testing and Commissioning of Traction & Power Supply works for Mumbai Metro Line 3 (Colaba-Bandra-SEEPZ). This order has been secured against stiff competition from other major multi-national companies. Meanwhile, shares of the company were trading at Rs 1284 apiece, down 0.56 per cent from the previous close at 11:06 hours on BSE.

23-02-2018 11:00

Merck Q4 net profit jumps 49.84% at Rs 27.27 cr

The company reported standalone net profit of Rs 27.27 crore for the quarter ended December 31, 2017 as compared to Rs 18.20 crore in the same period last year, registering a year-on-year growth of 49.84 per cent. Net revenue of the company rose substantially by 26.72 per cent at Rs 304.13 crore in October-December quarter of this fiscal as against Rs 240.01 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 20.50 per cent to Rs 273.41 crore from Rs 226.89 crore in year ago period. Other Income dipped by 33.58 per cent at Rs 5.40 crore versus (Dec'16 Rs 8.13 crore). Operating Profit surged by 24.57 per cent to Rs 30.72 crore as against Rs 24.66 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 1.66 per cent in December quarter. Taxation increased by 228.32 per cent at Rs 18.78 crore (Dec'16 Rs 5.72 crore).

23-02-2018 10:53

ITD Cementation Indi Q4 net profit up 36.82% at Rs 17.80 cr

The company reported standalone net profit of Rs 17.80 crore for the quarter ended December 31, 2017 as compared to Rs 13.01 crore in the same period last year, registering a year-on-year growth of 36.82 per cent. Net revenue of the company declined substantially by 30.70 per cent at Rs 467.43 crore in October-December quarter of this fiscal as against Rs 674.53 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 37.66 per cent to Rs 391.06 crore from Rs 627.27 crore in year ago period. Other Income grew by 138.07 per cent at Rs 14.57 crore versus (Dec'16 Rs 6.12 crore). Operating Profit surged by 60.54 per cent to Rs 76.37 crore as against Rs 47.57 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 131.77 per cent in December quarter. Interest grew by 4.46 per cent y-o-y to Rs 21.07 crore, while Taxation increased by 31.60 per cent at Rs 15.70 crore (Dec'16 Rs 11.93 crore).

23-02-2018 10:53

Visaka Indus. Q3 net profit zooms 164.56% at Rs 14.26 cr

The company reported standalone net profit of Rs 14.26 crore for the quarter ended December 31, 2017 as compared to Rs 5.39 crore in the same period last year, registering a year-on-year growth of 164.56 per cent. Net revenue of the company rose substantially by 20.34 per cent at Rs 241.84 crore in October-December quarter of this fiscal as against Rs 200.97 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 14.71 per cent to Rs 207.41 crore from Rs 180.82 crore in year ago period. Other Income grew by 130.23 per cent at Rs 0.99 crore versus (Dec'16 Rs 0.43 crore). Operating Profit surged by 59.35 per cent to Rs 34.42 crore as against Rs 21.60 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 32.37 per cent in December quarter. Interest grew by 3.40 per cent y-o-y to Rs 4.87 crore, while Taxation increased by 138.56 per cent at Rs 7.61 crore (Dec'16 Rs 3.19 crore).

23-02-2018 10:53

Adani Transmission bags LOI from PFC Consulting Limited

Adani Transmission Ltd (ATL), the largest private power transmission companies operating in India has said that it has received the LOI from PFC Consulting Limited (A wholly owned subsidiary of Power Finance Corporation Limited) to construct, own, operate and maintain the transmission project in the state of Rajasthan. The project “Fatehgarh-Bhadla Transmission Limited” has approximately 200 Ckt kms of line at voltage level of 765 KV and one substation at voltage level of 400 KV. This project is primarily being constructed to wheel out renewable energy from state of Rajasthan to different beneficiaries within & outside of the state. This project has been awarded to ATL through a Tariff Based Competitive Bidding Process. With this project, ATL will strengthen its existing significant presence in Rajasthan with 2 operational transmission projects (i.e. Aravali & Maru transmission company Ltd) and 4 under construction assets i.e. Suratgarh Bikaner, PPP-8, PPP-9 & PPP-10. On completion of this acquisition, apart from largest distribution network, the cumulative transmission network of ATL will reach around 12000 ckt kms, out of which approximate 9000 ckt kms are under operation. The transformation capacity of ATL will also increase to 19,300 MVA from 35 substations (Including 8 EHV Substations under acquisition) spread across the Country. Meanwhile, shares of the company were trading at Rs 210.10 apiece, up 1.23 per cent from the previous close at 10:10 hours on BSE.

23-02-2018 10:02

Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Investor Presentation

Dear Sir/Madam,

This is in furtherance to our letter dated February 9, 2018, wherein we shared the Corporate Presentation of the Company.

In this respect, please take note that there was a small typographical error in the 4th block on page no 6, wherein it was inadvertently mentioned '22.1 mn patients' instead of '11.4 mn patients'

We request you to kindly ignore the said error and take on record the revised Corporate Presentation of the Company.

The aforesaid presentation is also available on the Company's website - www.lalpathlabs.com

Thank You.

19-Feb-2018 04:25 PM

Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Investor Presentation

Dear Sir/Madam,

This is in furtherance to our letter dated February 9, 2018, wherein we shared the Corporate Presentation of the Company.

In this respect, please take note that there was a small typographical error in the 4th block on page no 6, wherein it was inadvertently mentioned '22.1 mn patients' instead of '11.4 mn patients'

We request you to kindly ignore the said error and take on record the revised Corporate Presentation of the Company.

The aforesaid presentation is also available on the Company's website - www.lalpathlabs.com

Thank You.

19-Feb-2018 04:24 PM

Dr. Lal Pathlabs Ltd - Investor Presentation

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation

19-Feb-2018 04:20 PM

Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Dear Sir/Madam,

Pursuant to Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Financial Results Conference Call Transcript of the Company for Q3 9M FY18.

We request you to please take the same on record.

19-Feb-2018 12:51 PM

Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

19-Feb-2018 12:51 PM

Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Investor Presentation

Dear Sir/Madam,

This is in furtherance to our letter dated February 9, 2018, wherein we shared the Corporate Presentation of the Company.

In this respect, please take note that there was a small typographical error in the 4th block on page no 6, wherein it was inadvertently mentioned '22.1 mn patients' instead of '11.4 mn patients'

We request you to kindly ignore the said error and take on record the revised Corporate Presentation of the Company.

The aforesaid presentation is also available on the Company's website - www.lalpathlabs.com

Thank You.

19-Feb-2018 04:25 PM

Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Investor Presentation

Dear Sir/Madam,

This is in furtherance to our letter dated February 9, 2018, wherein we shared the Corporate Presentation of the Company.

In this respect, please take note that there was a small typographical error in the 4th block on page no 6, wherein it was inadvertently mentioned '22.1 mn patients' instead of '11.4 mn patients'

We request you to kindly ignore the said error and take on record the revised Corporate Presentation of the Company.

The aforesaid presentation is also available on the Company's website - www.lalpathlabs.com

Thank You.

19-Feb-2018 04:24 PM

Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Dear Sir/Madam,

Pursuant to Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Financial Results Conference Call Transcript of the Company for Q3 9M FY18.

We request you to please take the same on record.

19-Feb-2018 12:51 PM

Corporate Details

About Management

Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company. Subsequently, Late Dr. Major S.K. Lal and (Hony.) Brig. Dr. Arvind Lal entered into a partnership under the name 'Central Clinical Laboratory', pursuant to a partnership deed dated March 21, 1975, with the partnership deemed to have commenced from December 1, 1974. The partnership firm was formed to provide pathology services under the name `Central Clinical Laboratory' and to maintain a blood bank for the supply of blood to patients and hospitals under the name `Blood Transfusion Centre', both to be undertaken at the Registered Office of the Company. On December 5, 1977, following the demise of Late Dr. Major S.K. Lal, Late Ms. Vimla Lal, wife of Late Dr. Major S.K. Lal, was inducted into the partnership with (Hony.) Brig. Dr. Arvind Lal. Following Late Ms. Vimla Lal's demise, Dr. Vandana Lal was inducted into the partnership by a deed of partnership dated January 2, 2007. Accordingly, as on date, Central Clinical Laboratory is a 50:50 partnership between Dr. Vandana Lal and (Hony.) Brig. Dr. Arvind Lal. the Company was incorporated as `Dr. Lal PathLabs Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. the Company was converted into a public company pursuant to a special resolution of the shareholders of the Company at an EGM held on August 7, 2015. Consequently, the name of the Company was changed to `Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015. Awards and accreditations : 2001 -Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials. 2002 -Fully accredited by the College of American Pathologists' Laboratory Accreditation Program. 2008 -Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category. 2010 -Franchisor of the Year in healthcare, at the Franchise Plus Awards. -Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards. 2012 -Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards. -Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare. 2013 -Best Diagnostic Company in India at the VC Circle Healthcare Summit. 2014 -Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions. -Received an NABL certificate of accreditation under standard ISO 15189:2012 for "Medical Laboratories - Requirements for Quality and Competence" for medical testing, for National Reference Laboratory. 2015 -Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the 'Cloud' category. -Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India. Major events and milestones : 2005 & 2007 -Investment by WestBridge I Investments Holdings. 2008 -Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited. 2010 -Establishment of the National Reference Laboratory. 2010 & 2013 -Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings. 2013 -Investment pursuant to purchase of shares by WestBridge Crossover Fund, LLC from WestBridge I Investment Holdings. -Investment by SIH. 2014 -Acquisition of APL Clinical Institute of Clinical Laboratory & Research Private Limited. 2015 -Amalgamation of Sanya Chemicals Private Limited, Amolak Diagnostics Private Limited, Medex Healthcare Private Limited, Medicave Diagnostic Centre Private Limited, Medicave Medical Systems Private Limited and the Company.

Registered Office

12th Floor, Tower B, SAS Tower, Sector 38, Medicity,

0124-3016500,,,      0124-4234468,

cs@lalpathlabs.com

https://www.lalpathlabs.com

Registrar Details

Link Intime India Pvt. Ltd.